AC
NBIX icon

Aristides Capital’s Neurocrine Biosciences NBIX Stock Holding History

Aristides Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,206
Closed -$215K – 172
2022
Q2 		$215K Hold
2,206
– – 0.15% 118
2022
Q1 		$207K Buy
+2,206
New +$187K 0.13% 145

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aristides Capital's NBIX Position: Q3 2022 in Review

Aristides Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 2,206 shares — an estimated $215K sold.

Aristides Capital first reported a position in NBIX in Q1 2022 and held it in 2 quarters. The position peaked at $215K in Q2 2022. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Aristides Capital reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Aristides Capital sold 2,206 Neurocrine Biosciences shares in Q3 2022, an estimated $215K.
  • Aristides Capital first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 2 quarters.
  • Aristides Capital's Neurocrine Biosciences position peaked at $215K in Q2 2022.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Aristides Capital's 13F filing for Q3 2022, filed 15 Nov 2022.